3rd Gene Therapy Comparability Summit

Memo

In the context of ever-important gene therapy scale-up to achieve commercial goals and mounting regulatory scrutiny, the 3rd Annual Gene Therapy Comparability Summit is the only event focused on comparability of gene therapy. Join 150+ Quality Assurance, CMC, Regulatory, Analytical and Process Development experts from pharma and biotechs to provide you with hands-on, practical insights into exactly what it takes to ensure you can maintain safety, quality, consistency, and efficacy while adapting manufacturing processes, methods and platforms, to adhere to regulatory demands and avoid costly delays to clinical programs.With two recent approvals there has been a resurgence surrounding gene therapy, so comparability continues to be of upmost importance, and is at the forefront of the communities minds due to push-back from regulators.This is your exclusive opportunity to join likeminded individuals from across the Gene Therapy space to gain a hands-on and practical insight into methods to improve your comparability assessmentsURLs:Brochure: https://go.evvnt.com/1459398-2?pid=5569 Tickets: https://go.evvnt.com/1459398-3?pid=5569   Date and Time: On Tuesday March 28, 2023 at 9:00 am to Thursday March 30, 2023 at 5:00 pmVenue details: Hilton Boston Back Bay, 40 Dalton St, Boston, Massachusetts, 02115, United States   Prices:Drug Developer Pricing - 2 Day Conference + Pre Conference Workshop Day: USD 4297.00,Drug Developer Pricing - 2 Day Conference Only: USD 2999.00,Standard Pricing - 2 Day Conference + Pre Conference Workshop Day: USD 5097.00,Standard Pricing - 2 Day Conference Only: USD 3599.00Speakers: Ilya Shestopalov, Senior Director - Analytical Development and Product Lead, bluebird bio, Miloud Nichane, Quality Control and Regulatory Advisor, GeneQuine, Rachel Chevalier, Associate Director - Quality Control, bluebird bio, Santoshkumar Khatwani, Director - Analytical Development, Late Stage, Chemistry, Manufacturing and Controls Analytical Team Lead, Sangamo Therapeutics, Christopher Bravery, Regulatory Scientist Consulting on Advanced, Biologicals Ltd, Marco Thomann, Principal Scientist - Gene Therapy Technical Development, Roche Diagnostics GmbH, Mariska ter Haak, Director Analytical Development, IN8bio, Xiaohui Lu, Executive Director - Analytical Development, Ultragenyx Gene Therapy, Elizabeth Pratico, Director - Process Development, CRISPR Therapeutics, Omar Tounekti, Manager, Cells, Gene Therapies and Radiopharmaceuticals Division, Health Canada, Shilpa Suravajhala, Senior Scientist, bluebird bio, Victor LU, CTO, Innovative Cellular Therapeutics, David Dobnik, Senior Associate - Research, National Institute of Biology, Joshua Kidder, Sr. Director Quality Control, Ultragenyx Pharmaceutical Inc, Julia Sable, Director - Chemistry, Manufacturing, and Controls Project Management, Tmunity Therapeutics Inc., Tayler Renshaw, Associate Director - Regulatory Affairs and CMC, Astellas Innovation Management, Elena Peletskaya, Director, Gene Delivery Analytics, Bristol Myers Squibb, Ivan Budyak, Director - Analytical Development and Biophysical Characterization, Eli Lilly and Co., Marc d'Anjou, Senior Director - Regulatory Chemistry Manufacturing and Control, bluebird bio, Russel Beste, Regulatory Project Manager, Consultant, Max Tejada, Executive Director and Head of Analytical Development, Kite Pharma Inc, Mia Wang, Senior Director and Team Leader - Chemistry, Manufacturing and Controls, Cell Therapy, Sana Biotechnology, Ronald Toth, Senior Scientist, Sanofi